κ-opioid

The κ-opioid receptor (KOR, or kappa-opioid receptor) is one of three classical opioid receptor subtypes — alongside the mu (μ) and delta (δ) receptors — found throughout the brain and spinal cord. It belongs to the G-protein-coupled receptor family and is a primary target of the body's own dynorphin peptides.

While all opioid receptors share structural similarities, the κ receptor produces a strikingly different profile from the better-known μ receptor. Rather than the euphoria and sedation associated with μ activation, κ activation is characterised by dysphoria, dissociation, and perceptual distortion — placing it at the centre of some of the most unusual psychoactive experiences documented in pharmacology.

How it works · its role

When a substance binds to and activates the κ-opioid receptor, it inhibits neuronal activity through a cascade of intracellular signals: adenylyl cyclase is suppressed, potassium channels open, and calcium channels close. The net effect is a reduction in the rate at which the neuron fires.

This inhibition plays out differently depending on the circuit involved. In reward pathways, κ activation suppresses dopamine release, which is thought to underlie the dysphoric, anhedonic quality of κ agonism. In sensory and limbic circuits, the same mechanism produces analgesia, altered time perception, and — at higher levels of activation — vivid hallucinations that are qualitatively unlike those produced by classic psychedelics.

The receptor also has a documented role in the stress response. Repeated stress raises dynorphin levels in the brain, and chronic κ activation is associated with depressive and anhedonic states.

Relevance to substances & effects

Salvinorin A, the active compound in Salvia divinorum, is the most studied selective κ-opioid agonist in psychopharmacology. It produces an intensely disorienting, short-lived experience — ego dissolution, spatial distortion, and a distinctive sense of derealization — that is mechanistically separate from serotonergic psychedelics and proceeds through κ activation alone.

Several mixed-action opioids (such as butorphanol and pentazocine) carry partial κ agonist activity alongside their μ effects, and their tendency to produce dysphoric or hallucinatory side effects at higher doses is attributed to this κ component. Nalbuphine follows a similar profile.

Ibogaine, the long-acting psychoactive found in the iboga plant, acts across multiple receptor systems including κ-opioid, which may contribute to the aversive and visionary character of the experience at high doses. Research into κ antagonists — compounds that block the receptor — is ongoing as a possible avenue for treating depression and addiction, since blocking κ activity can relieve stress-induced anhedonia in animal models.

Tolerance & dependence

Repeated κ-opioid receptor activation produces receptor downregulation and desensitisation, meaning progressively less response to the same dose — the same tolerance mechanism seen across the opioid receptor family.

The abuse liability of selective κ agonists is considered low precisely because their dysphoric effects make repeated dosing aversive for most people. However, chronic activation — whether from repeated use of κ-active substances or from sustained stress-driven dynorphin release — is thought to contribute to a persistent low-mood state that can persist after use stops. This is an active area of research rather than a firmly settled finding.